Abstract
Inherited arrhythmogenic diseases (IADs – also called cardiac channelopathies) are defined as a group of genetic diseases characterized by electrically unstable substrate in a structurally normal heart (1). Genetic testing in cardiac channelopathies has completed its transition from a research-based activity to that of a clinical genetic service. In parallel, the advancements of the sequencing technologies are providing ways to sequence several genes at a relatively low cost. This is progressively changing the approach to the genetic diagnosis of IADs. Indeed, while Sanger-based genetic testing was traditionally limited to the well characterized, most prevalent genes, next-generation sequencing (NGS) allows screening even the “minor” disease genes with very short turnaround time. This approach to genetic testing is highly efficient, but it is also generating remarkable interpretative problems mostly related to the high prevalence of variants of unknown significance (VUS), i.e., not clearly related to disease pathophysiology. This issue is relevant to several genetic diseases of the heart but is particularly evident in IADs, where the familial co-segregation analysis is hampered by the incomplete penetrance and the variable expressivity. How to design the most appropriate screening approach is challenging and it requires in-depth knowledge of the specific diseases of interest. In this Opinion article, we will review the available NGS approaches and try to outline the available strategies to optimize the performance of this genetic testing methodology.
Highlights
Inherited arrhythmogenic diseases (IADs – called cardiac channelopathies) are defined as a group of genetic diseases characterized by electrically unstable substrate in a structurally normal heart (1)
There are still some limitations that need to be considered in terms of sensitivity of the uncovered regions
The high-throughput capability is revealing itself as a double edge sword: on the one hand, it allows amazingly short turnaround time and reduced costs, but on the other hand, it reveals an increased rate of variants of unknown significance (VUS) and tests that are not conclusive
Summary
Inherited arrhythmogenic diseases (IADs – called cardiac channelopathies) are defined as a group of genetic diseases characterized by electrically unstable substrate in a structurally normal heart (1). The advancements of the sequencing technologies are providing ways to sequence several genes at a relatively low cost This is progressively changing the approach to the genetic diagnosis of IADs. while Sanger-based genetic testing was traditionally limited to the well characterized, most prevalent genes, next-generation sequencing (NGS) allows screening even the “minor” disease genes with very short turnaround time. While Sanger-based genetic testing was traditionally limited to the well characterized, most prevalent genes, next-generation sequencing (NGS) allows screening even the “minor” disease genes with very short turnaround time This approach to genetic testing is highly efficient, but it is generating remarkable interpretative problems mostly related to the high prevalence of variants of unknown significance (VUS), i.e., not clearly related to disease pathophysiology. In this Opinion article, we will review the available NGS approaches and try to outline the available strategies to optimize the performance of this genetic testing methodology
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.